Global edition
Region
NewsCase StudiesWebcastsInterviewsEventsPodcastsMagazine
Sign inSubscribe
Follow Pharma Now@pharmanow.live
Editions & local coverage
United StatesUnited KingdomGermanyFranceItalyIndiaSwitzerlandSingapore

A global knowledge and leadership platform for pharma. We turn complexity into clarity professionals can act on.

Get the Pharma Now app

Read offline, save stories and never miss an edition.

Get it onGoogle PlayDownload on theApp Store
Verticals
  • Leadership
  • AI in Pharma
  • Manufacturing
  • Marketing
  • HR in Pharma
  • Microbiology & CCS
  • Regulatory Landscape
Formats
  • News & Analysis
  • Interviews
  • Case Studies
  • Webcasts
  • Podcasts
  • Events
  • Magazine
Knowledge Hub
  • Knowledge Hub
  • Research Papers
  • Buyer’s Guides
  • Companies
  • Newsletter Archive
  • Glossary
Company
  • Advisory Board
  • Contributors
  • Write for Us
  • Submit a PR
  • Contact
  • Advertise
Account
  • Subscribe
  • Sign in
  • My Account
  • Partner with us
Frequently asked

Pharma Now is a leading monthly B2B magazine focused on delivering in-depth content related to the pharmaceutical and biopharma sectors. It covers the latest trends, technological innovations, leadership insights, market developments, and interviews with industry experts.

Pharma Now provides comprehensive coverage, including: - Industry news and updates - Interviews with global pharma leaders - Market insights and trends - Innovations in AI, manufacturing, and pharma operations - Case studies, thought leadership articles, and regulatory updates

Pharma Now caters to a wide range of professionals within the pharmaceutical industry, including C-level executives, R&D professionals, quality managers, regulatory affairs specialists, and business leaders looking to stay informed about global trends and innovations.

You can subscribe to Pharma Now by visiting the Pharma Now website and choosing between print and digital editions.

Yes, Pharma Now welcomes contributions from industry experts. Contributors can submit articles, thought leadership pieces, and case studies. You can register on the contributors' page to submit content and gain recognition for your insights.

Pharma Now offers multiple advertising packages tailored to help companies promote their products, services, and innovations. From full-page ads to special event coverage, advertisers can reach a targeted audience of pharma professionals. For details, visit the Advertise With Us section on the website.

Copyright © 2026 Tantragyan Technologies Pvt Ltd. All Rights Reserved.
Privacy PolicyTerms of UseContact UsAdvertise
Home/Case Studies/Digital Batch Records
Q&A Case studyDigital Batch Records

Retiring Paper Batch Records Across a Commercial Biologics Campus

Takeda Osaka replaced paper batch records with an eBR platform for three commercial biologics products — and paid down years of review-by-exception debt.

Reduction in batch review lead time
85%
Kenji Takahashi
The practitioner
Kenji Takahashi
Director, MES & Digital Operations, Takeda
Interview by Mrudula Kulkarni
Managing Editor - Pharma Now
14 Jul 2026 · 10 min read
The challenge
Paper batch records at the Osaka campus were averaging 340 pages per lot and driving a QA review backlog of nearly two weeks at peak.
The approach
The team defined a lean eBR data model per product, ran a structured user acceptance testing programme with shop-floor operators, and…
The result
Review lead time dropped from thirteen days to under two, right-first-time climbed above 96 percent, and the last two regulatory…
Retiring Paper Batch Records Across a Commercial Biologics Campus

The challenge

Paper batch records at the Osaka campus were averaging 340 pages per lot and driving a QA review backlog of nearly two weeks at peak. Right-first-time on batch records sat around 71 percent, and every audit surfaced observations tied to legibility, contemporaneity, or transcription errors.

The approach

The team defined a lean eBR data model per product, ran a structured user acceptance testing programme with shop-floor operators, and staged the rollout product-by-product. A change management workstream ran in parallel, retraining QA reviewers on review-by-exception and rewiring downstream release workflows.

The result

Review lead time dropped from thirteen days to under two, right-first-time climbed above 96 percent, and the last two regulatory inspections closed with no data integrity observations. The eBR platform is now being extended to two additional commercial products.

Q

How did you get operator buy-in on eBR?

We ran user acceptance testing with actual shop-floor operators — not managers or IT — and iterated the UI three times based on their feedback.

The unlock was making the eBR faster than paper for the common case. Operators stopped seeing it as a compliance burden once they realised it saved them 40 minutes per lot on data entry alone.

Q

What was the hardest technical challenge?

Modelling the review-by-exception logic. Paper batch records are reviewed page-by-page; eBR only surfaces the exceptions, which means the system has to know what "normal" looks like for every parameter.

We spent three months building the exception library with QA reviewers before the first product went live. Every subsequent product plugged into the same library.

Q

What changed for QA reviewers?

The job shifted from checking every entry to investigating exceptions. That required a real retraining programme — QA reviewers had built decades of muscle memory around page-by-page verification.

We paired every reviewer with a senior colleague for their first month on eBR. By month two, review times had collapsed and everyone was confident in the new workflow.

A 340-page paper record is not a document. It's a two-week bottleneck disguised as compliance.

Kenji Takahashi, Director MES & Digital Operations
Measured impact
85%
Reduction in batch review lead time
96%
Right-first-time on batch records
0
Data integrity observations at last two inspections

The method, in brief

1
Define a lean eBR data model per product — Started with the leanest possible data model. Every field had to earn its place — if a paper section wasn't adding review value, it didn't make the eBR.
2
Iterate the UI with shop-floor operators — Three rounds of user acceptance testing with actual operators before the first product went live. Every round produced concrete UI changes.
3
Build the review-by-exception library first — Three months building the exception library with QA reviewers before flipping the switch. Every product going forward reuses the same library.
4
Stage the rollout product-by-product — One commercial product per wave, three months apart. Each wave fed lessons into the next. First three products live in nine months.
5
Retrain QA reviewers on exception investigation — Paired every reviewer with a senior colleague for their first month on eBR. By month two, review times had dropped and confidence was uniform across the QA team.
Download PDF
Share

Discussion

Loading discussion…
Case facts
SiteOsaka, Japan
SectorBiologics
RegionAPAC
ProgrammeElectronic batch records (eBR)
TeamQA, Manufacturing IT, Operations
Reviewed byPriya Nair, Chief Quality Officer
Pitch your own result
About the practitioner
Kenji Takahashi
Kenji Takahashi
Director, MES & Digital Operations, Takeda

Kenji led the eBR rollout across Takeda's Osaka campus, replacing paper batch records for three commercial products.

Independently reviewed

Method and data verified by a Pharma Now editor and an external subject expert before publication.

More case studies

All case studies
Closing the Annex 1 Gap on a Legacy Fill-Finish LineQ&A
Sterile Manufacturing

Closing the Annex 1 Gap on a Legacy Fill-Finish Line

58%Reduction in manual interventions per batch
9 min
A Quality 4.0 Analytics Layer Above Legacy LIMS and MESQ&A
Quality 4.0

A Quality 4.0 Analytics Layer Above Legacy LIMS and MES

47%Fewer trend-triggered investigations year on year
8 min
From Batch to Continuous: Rewiring an OSD Product for Steady-State ManufactureQ&A
Continuous Manufacturing

From Batch to Continuous: Rewiring an OSD Product for Steady-State Manufacture

38%Reduction in end-to-end cycle time
11 min
Have a result worth sharing?

Pitch a case study from your site.

If you have changed a method and have the data to show for it, our editors would like to hear from you — in confidence, with no obligation to publish.